Lyncis™ is a targeted oncology data solution developed by M2GEN, a world-recognized bioinformatics leader. Based on our belief that effective research is rooted in teamwork, we take a collaborative approach to the fight against cancer. Led by industry trailblazers and scientific experts, our team specializes in creating and delivering oncology-focused bioinformatics solutions—such as our groundbreaking Lyncis dataset—to help researchers better predict and meet the unique needs of cancer patients.
Effectively, M2GEN is breaking down the barriers to scientific collaboration. By leveraging shared clinical and molecular data, we are expediting the discovery and development of precision cancer medicine. As such, we have essentially turned the traditional oncology research process on its head
Cohort studies are fundamental to epidemiological research and critical to the discovery of novel cancer therapies. Through Lyncis™, scientists can study—at an unprecedented resolution—subsets of a large population of patients with a certain set of characteristics and exposures who were observed between 2011 and 2015 for the incidence of new cancers and cancer-related outcomes.
Lyncis™ focuses exclusively on five patient cohorts. These groups consist of individuals who were diagnosed with one of the following types of cancer:
All Lyncis™ data was collected through the Oncology Research Information Exchange Network® (ORIEN®), a unique alliance of leading cancer centers and hospitals facilitated by M2GEN, which serves as its operational engine. To drive cancer research forward, ORIEN members share de-identified patient data—which is made available with the patients’ full consent—with each other and with biopharmaceutical companies.
Based on our data-gathering protocol for Lyncis™, each prospective patient consented to share the clinical data from their initial visit form as well as two follow-up forms at six-month intervals. As a result, Lyncis™ incorporates a wealth of longitudinal clinical data, including:
Longitudinal clinical data is invaluable to researchers. However, we recognize that it is not enough on its own to facilitate the development of precision cancer therapies. When analyzing clinical data, scientists must take into account that each patient’s disease is different—each has its own unique set of molecular features that contributed to its development and growth.
To address this research challenge, M2GEN has seamlessly integrated multiple molecular data types into Lyncis™, helping scientists to disentangle the sources of disease variability and ultimately develop and guide personalized cancer treatment.
In addition to clinical data, the Lyncis™ targeted disease dataset is a rich source of molecular data, including tumor whole exome sequencing (WES), germline WES and RNA sequencing. Through the analysis of this extensive and highly organized information, our research partners can build specific molecular profiles of tumors. Based on these profiles, researchers can identify the unique molecular “signatures” that distinguish individual patients, then classify those patients into groups that are likely to benefit from certain therapies.
As such, our research partners can utilize Lyncis™ to power investigative studies. Based on the insights gleaned, they can create specific sets of criteria, such as the presence of certain tumor biomarkers, to select patients for clinical trials.
Working Together to Revolutionize Cancer Treatment
By integrating shared data through bioinformatics, M2GEN is transforming the understanding of cancer, advancing the conduct of clinical trials, and changing the way oncologists select therapies for their patients. Along with our research partners, we are driving science forward and revolutionizing the field of precision oncology.
If you would like to gain access to this data or find out if M2GEN has your dataset of interest, please contact us today.